Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
GlobalData on MSN1d
Novo Nordisk and Valo expand cardiometabolic drug partnershipNovo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Novo Nordisk warns that adding liraglutide to the 503B Bulks List would contradict Congress’ and the FDA’s intent to restrict patient exposure to unapproved drugs. The company argues that such ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback